Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DENTSPLY SIRONA Inc.XRAY · Entity 4448 | Director | January 09, 2026 | January 13, 2026 |
| G1 Therapeutics, Inc.GTHX · Entity 87413 | Director | June 23, 2022 | June 24, 2022 |
| Merck & Co., Inc.MRK · Entity 2807 | Exe V-P & Pres. MMD | February 22, 2016 | February 24, 2016 |
| PUBLIC SERVICE ENTERPRISE GROUP INCPEG · Entity 203 | Director | May 01, 2026 | May 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DENTSPLY SIRONA Inc.
Report date January 09, 2026 · Filed January 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 57,748.066 |
Reported balance
After 2026-01-09 transaction · row 1
1 source rowRow 1 · 2026-01-09 · Grant · Acquired 201.508 · Balance 57,748.066 F1: Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents dividends on restricted stock units (RSUs) awarded to the Reporting Person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards. The dividends vest simultaneously with the RSUs to which they relate. Each RSU converts to common stock on a 1:1 basis.
G1 Therapeutics, Inc.
Report date June 23, 2022 · Filed June 24, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,389 |
Reported balance
After 2022-06-23 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-06-23 · Grant · Acquired 10,000 · Balance 14,389 F1: Represents a restricted stock unit ("RSU") award that vests in its entirety twelve months after June 23, 2022, subject to the Reporting Person's continued service as a director. F2: Each RSU represents a contingent right to receive one share of Issuer common stock F3: Represents 4,389 shares of common stock and 10,000 restricted stock units |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.30 · Expires 2032-06-23 | Direct | 30,000 |
Reported balance
After 2022-06-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-23 · Grant · Acquired 30,000 · Balance 30,000 F4: The shares underlying this option will vest in their entirety twelve months after June 23, 2022, subject to the Reporting Person's continued service as a director. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit ("RSU") award that vests in its entirety twelve months after June 23, 2022, subject to the Reporting Person's continued service as a director.
F2: Each RSU represents a contingent right to receive one share of Issuer common stock
F3: Represents 4,389 shares of common stock and 10,000 restricted stock units
F4: The shares underlying this option will vest in their entirety twelve months after June 23, 2022, subject to the Reporting Person's continued service as a director.
Merck & Co., Inc.
Report date February 22, 2016 · Filed February 24, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 133,759.3521 |
Reported balance
After 2016-02-22 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2016-02-22 · Grant · Acquired 14,557 · Balance 133,759.3521 F1: Distribution of net after tax shares of common stock on satisfaction of performance share units granted on 03/29/2013. Performance shares were paid out at 105 percent of target awards. F2: Holdings include shares acquired in dividend reinvestment transactions. |
| Common Stock - 401(k) PlanSEC Table I · non-derivative | IndirectBy 401(k) | 719.079 |
Reported balance
Holding disclosure · report date 2016-02-22 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 719.079 F3: Includes shares acquired and dividends earned through January 8, 2016, in the Merck U.S. Savings Plan, a 401(k) plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Distribution of net after tax shares of common stock on satisfaction of performance share units granted on 03/29/2013. Performance shares were paid out at 105 percent of target awards.
F2: Holdings include shares acquired in dividend reinvestment transactions.
F3: Includes shares acquired and dividends earned through January 8, 2016, in the Merck U.S. Savings Plan, a 401(k) plan.
PUBLIC SERVICE ENTERPRISE GROUP INC
Report date May 01, 2026 · Filed May 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,933.239 |
Reported balance
After 2026-05-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-01 · Grant · Acquired 2,246 · Balance 11,933.239 F1: 2026 Restricted Stock Unit grant under the PSEG 2021 Equity Compensation Plan For Outside Directors. F2: Amount includes accumulated dividend reinvestment equivalents that are exempt from Section 16. |
Filing footnotes · ownership attribution and instrument terms
F1: 2026 Restricted Stock Unit grant under the PSEG 2021 Equity Compensation Plan For Outside Directors.
F2: Amount includes accumulated dividend reinvestment equivalents that are exempt from Section 16.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CDK Global, Inc.
Report date July 06, 2022 · Filed July 06, 2022
Section 16 reporting ended · disclosed 2022-07-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-07-06 transaction · row 1
1 source rowRow 1 · 2022-07-06 · Disposition to issuer · Disposed 31,684 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), among the Company, Central Parent LLC ("Parent") and Central Merger Sub Inc. ("Merger Sub"), on July 6, 2022, Merger Sub merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), and, at the effective time of the Merger, each share of common stock, par value $0.01 per share (each, a "Share"), of the Company was canceled and converted into the right to receive $54.87 in cash without interest. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.67 | Direct | 0 |
Reported balance
After 2022-07-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-07-06 · Disposition to issuer · Disposed 15,384 · Balance 0 F2: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Merger, whether then unvested or vested, by virtue of the Merger and without any action by the holder, was canceled and converted into only the right to receive an amount in cash, without interest, equal to the product of (x) the number of Shares issuable under such option and (y) the excess, if any, of (i) $54.87 over (ii) the exercise price payable in respect of each Share issuable under such option (the "Option Consideration"); provided, however, that the Option Consideration for each option with an exercise price equal to or greater than $54.87 was $0. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), among the Company, Central Parent LLC ("Parent") and Central Merger Sub Inc. ("Merger Sub"), on July 6, 2022, Merger Sub merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), and, at the effective time of the Merger, each share of common stock, par value $0.01 per share (each, a "Share"), of the Company was canceled and converted into the right to receive $54.87 in cash without interest.
F2: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Merger, whether then unvested or vested, by virtue of the Merger and without any action by the holder, was canceled and converted into only the right to receive an amount in cash, without interest, equal to the product of (x) the number of Shares issuable under such option and (y) the excess, if any, of (i) $54.87 over (ii) the exercise price payable in respect of each Share issuable under such option (the "Option Consideration"); provided, however, that the Option Consideration for each option with an exercise price equal to or greater than $54.87 was $0.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 11, 2015 Filed Feb 11, 2015 19:19 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 135,864 | $58.56 | $7,956,372.46 |
DisclosureSEC source: 0001225208-15-003523 · doc4.xml · nonDerivative · entry 4 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,230.2077 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.4000 to $58.7900, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 11, 2015 Filed Feb 11, 2015 19:19 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 34,680 | $44.19 | $1,532,509.20 |
DisclosureSEC source: 0001225208-15-003523 · doc4.xml · nonDerivative · entry 3 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,094.2077 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2015 Filed Feb 11, 2015 19:19 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 48,144 | $33.49 | $1,612,342.56 |
DisclosureSEC source: 0001225208-15-003523 · doc4.xml · nonDerivative · entry 2 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,414.2077 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2015 Filed Feb 11, 2015 19:19 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 53,040 | $44.30 | $2,349,672.00 |
DisclosureSEC source: 0001225208-15-003523 · doc4.xml · nonDerivative · entry 1 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,270.2077 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 27, 2014 Filed Jun 30, 2014 20:23 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 42,956 | $0.00 Strike: $23.45 | $0.00 |
DisclosureSEC source: 0001225208-14-015767 · doc4.xml · derivative · entry 8 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 42,956 shares Expires 2019-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 27, 2014 Filed Jun 30, 2014 20:23 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 22,108 | $0.00 Strike: $35.09 | $0.00 |
DisclosureSEC source: 0001225208-14-015767 · doc4.xml · derivative · entry 7 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,108 shares Expires 2016-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 27, 2014 Filed Jun 30, 2014 20:23 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 7,226 | $0.00 Strike: $31.84 | $0.00 |
DisclosureSEC source: 0001225208-14-015767 · doc4.xml · derivative · entry 6 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,226 shares Expires 2015-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 27, 2014 Filed Jun 30, 2014 20:23 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 72,290 | $58.26 | $4,211,253.95 |
DisclosureSEC source: 0001225208-14-015767 · doc4.xml · nonDerivative · entry 4 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,222.3873 F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.9600 to $58.5200, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F3 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| June 27, 2014 Filed Jun 30, 2014 20:23 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 7,226 | $31.84 | $230,075.84 |
DisclosureSEC source: 0001225208-14-015767 · doc4.xml · nonDerivative · entry 3 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,512.3873 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 27, 2014 Filed Jun 30, 2014 20:23 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 22,108 | $35.09 | $775,769.72 |
DisclosureSEC source: 0001225208-14-015767 · doc4.xml · nonDerivative · entry 2 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,286.3873 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 27, 2014 Filed Jun 30, 2014 20:23 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 42,956 | $23.45 | $1,007,318.20 |
DisclosureSEC source: 0001225208-14-015767 · doc4.xml · nonDerivative · entry 1 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,178.3873 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 09, 2014 Filed May 13, 2014 19:53 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 82,531 | $0.00 Strike: $58.22 | $0.00 |
DisclosureSEC source: 0001225208-14-012816 · doc4.xml · derivative · entry 3 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,531 Underlying: Common Stock · 82,531 shares Expires 2024-05-08 F3 · derivative.exercise_date: The option vests in three equal annual installments beginning May 9, 2015. Read SEC document |
| May 04, 2014 Filed May 6, 2014 20:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 7,659 | $58.22 | $445,906.98 |
DisclosureSEC source: 0001225208-14-012263 · doc4.xml · derivative · entry 4 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,659 shares Expires 2014-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| May 04, 2014 Filed May 6, 2014 20:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 3,449 | $58.22 | $200,800.78 |
DisclosureSEC source: 0001225208-14-012263 · doc4.xml · nonDerivative · entry 2 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,222.3873 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 04, 2014 Filed May 6, 2014 20:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 7,659 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-14-012263 · doc4.xml · nonDerivative · entry 1 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,671.3873 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2014 Filed Mar 7, 2014 19:04 UTC | Merck & Co., Inc. MRK · Entity 2807 | GiftCommon Stock | 14,175 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-14-007707 · doc4.xml · nonDerivative · entry 1 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,009.9678 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 24, 2014 Filed Feb 26, 2014 19:26 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 10,136 | $56.18 | $569,440.48 |
DisclosureSEC source: 0001225208-14-006294 · doc4.xml · nonDerivative · entry 1 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,184.9678 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 03/31/2011. Performance shares were paid out at 86 percent of target awards. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 10, 2014 Filed Feb 11, 2014 20:54 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $48.24 | $0.00 |
DisclosureSEC source: 0001225208-14-004045 · doc4.xml · derivative · entry 4 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2014-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2014 Filed Feb 11, 2014 20:54 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 50,000 | $54.68 | $2,734,155.00 |
DisclosureSEC source: 0001225208-14-004045 · doc4.xml · nonDerivative · entry 2 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,048.9678 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.61 to $54.78, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| February 10, 2014 Filed Feb 11, 2014 20:54 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 20,000 | $48.24 | $964,800.00 |
DisclosureSEC source: 0001225208-14-004045 · doc4.xml · nonDerivative · entry 1 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,048.9678 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 27, 2014 Filed Jan 28, 2014 15:09 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $47.79 | $0.00 |
DisclosureSEC source: 0001225208-14-002448 · doc4.xml · derivative · entry 3 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2014-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 27, 2014 Filed Jan 28, 2014 15:09 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 30,000 | $47.79 | $1,433,700.00 |
DisclosureSEC source: 0001225208-14-002448 · doc4.xml · nonDerivative · entry 1 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,048.9678 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| August 07, 2013 Filed Aug 7, 2013 20:57 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 9,969 | $0.00 Strike: $33.49 | $0.00 |
DisclosureSEC source: 0001225208-13-017461 · doc4.xml · derivative · entry 18 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,490 Underlying: Common Stock · 9,969 shares Expires 2020-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2013 Filed Aug 7, 2013 20:57 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 7,770 | $0.00 Strike: $36.56 | $0.00 |
DisclosureSEC source: 0001225208-13-017461 · doc4.xml · derivative · entry 17 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,861 Underlying: Common Stock · 7,770 shares Expires 2021-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2013 Filed Aug 7, 2013 20:57 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 4,662 | $0.00 Strike: $39.29 | $0.00 |
DisclosureSEC source: 0001225208-13-017461 · doc4.xml · derivative · entry 16 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,543 Underlying: Common Stock · 4,662 shares Expires 2022-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2013 Filed Aug 7, 2013 20:57 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 7,580 | $0.00 Strike: $23.45 | $0.00 |
DisclosureSEC source: 0001225208-13-017461 · doc4.xml · derivative · entry 15 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,956 Underlying: Common Stock · 7,580 shares Expires 2019-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2013 Filed Aug 7, 2013 20:57 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 3,902 | $0.00 Strike: $35.09 | $0.00 |
DisclosureSEC source: 0001225208-13-017461 · doc4.xml · derivative · entry 14 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,108 Underlying: Common Stock · 3,902 shares Expires 2016-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2013 Filed Aug 7, 2013 20:57 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 6,120 | $0.00 Strike: $44.19 | $0.00 |
DisclosureSEC source: 0001225208-13-017461 · doc4.xml · derivative · entry 13 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,680 Underlying: Common Stock · 6,120 shares Expires 2017-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2013 Filed Aug 7, 2013 20:57 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 9,360 | $0.00 Strike: $44.30 | $0.00 |
DisclosureSEC source: 0001225208-13-017461 · doc4.xml · derivative · entry 12 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,040 Underlying: Common Stock · 9,360 shares Expires 2018-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2013 Filed Aug 7, 2013 20:57 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 1,275 | $0.00 Strike: $31.84 | $0.00 |
DisclosureSEC source: 0001225208-13-017461 · doc4.xml · derivative · entry 11 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,226 Underlying: Common Stock · 1,275 shares Expires 2015-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2013 Filed Aug 7, 2013 20:57 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 50,638 | $48.55 | $2,458,611.62 |
DisclosureSEC source: 0001225208-13-017461 · doc4.xml · nonDerivative · entry 9 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,039.5265 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.5500 to $48.5527, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| August 07, 2013 Filed Aug 7, 2013 20:57 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 1,275 | $31.84 | $40,596.00 |
DisclosureSEC source: 0001225208-13-017461 · doc4.xml · nonDerivative · entry 8 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,677.5265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2013 Filed Aug 7, 2013 20:57 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 3,902 | $35.09 | $136,921.18 |
DisclosureSEC source: 0001225208-13-017461 · doc4.xml · nonDerivative · entry 7 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,402.5265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2013 Filed Aug 7, 2013 20:57 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 4,662 | $39.29 | $183,169.98 |
DisclosureSEC source: 0001225208-13-017461 · doc4.xml · nonDerivative · entry 6 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,500.5265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2013 Filed Aug 7, 2013 20:57 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 6,120 | $44.19 | $270,442.80 |
DisclosureSEC source: 0001225208-13-017461 · doc4.xml · nonDerivative · entry 5 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,838.5265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2013 Filed Aug 7, 2013 20:57 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 7,580 | $23.45 | $177,751.00 |
DisclosureSEC source: 0001225208-13-017461 · doc4.xml · nonDerivative · entry 4 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,718.5265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2013 Filed Aug 7, 2013 20:57 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 7,770 | $36.56 | $284,071.20 |
DisclosureSEC source: 0001225208-13-017461 · doc4.xml · nonDerivative · entry 3 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,138.5265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2013 Filed Aug 7, 2013 20:57 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 9,360 | $44.30 | $414,648.00 |
DisclosureSEC source: 0001225208-13-017461 · doc4.xml · nonDerivative · entry 2 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,368.5265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2013 Filed Aug 7, 2013 20:57 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 9,969 | $33.49 | $333,861.81 |
DisclosureSEC source: 0001225208-13-017461 · doc4.xml · nonDerivative · entry 1 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,008.5265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2013 Filed May 8, 2013 23:28 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 14,631 | $44.98 | $658,102.38 |
DisclosureSEC source: 0001225208-13-011725 · doc4.xml · derivative · entry 18 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,631 shares Expires 2013-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. Read SEC document |
| May 07, 2013 Filed May 8, 2013 23:28 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 6,588 | $44.98 | $296,328.24 |
DisclosureSEC source: 0001225208-13-011725 · doc4.xml · nonDerivative · entry 9 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,039.5265 F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 07, 2013 Filed May 8, 2013 23:28 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 14,631 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-13-011725 · doc4.xml · nonDerivative · entry 8 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,627.5265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2013 Filed May 8, 2013 23:28 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 6,571 | $0.00 Strike: $33.49 | $0.00 |
DisclosureSEC source: 0001225208-13-011725 · doc4.xml · derivative · entry 17 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,459 Underlying: Common Stock · 6,571 shares Expires 2020-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2013 Filed May 8, 2013 23:28 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (right to buy) · Derivative | 96,618 | $0.00 Strike: $44.98 | $0.00 |
DisclosureSEC source: 0001225208-13-011725 · doc4.xml · derivative · entry 16 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,618 Underlying: Common Stock · 96,618 shares Expires 2023-05-05 F4 · derivative.exercise_date: The option vests in three equal annual installments beginning May 6, 2014. Read SEC document |
| May 06, 2013 Filed May 8, 2013 23:28 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 9,141 | $0.00 Strike: $36.56 | $0.00 |
DisclosureSEC source: 0001225208-13-011725 · doc4.xml · derivative · entry 15 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,631 Underlying: Common Stock · 9,141 shares Expires 2021-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2013 Filed May 8, 2013 23:28 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 5,484 | $0.00 Strike: $39.29 | $0.00 |
DisclosureSEC source: 0001225208-13-011725 · doc4.xml · derivative · entry 14 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,205 Underlying: Common Stock · 5,484 shares Expires 2022-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2013 Filed May 8, 2013 23:28 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 8,918 | $0.00 Strike: $23.45 | $0.00 |
DisclosureSEC source: 0001225208-13-011725 · doc4.xml · derivative · entry 13 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,536 Underlying: Common Stock · 8,918 shares Expires 2019-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2013 Filed May 8, 2013 23:28 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 4,590 | $0.00 Strike: $35.09 | $0.00 |
DisclosureSEC source: 0001225208-13-011725 · doc4.xml · derivative · entry 12 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,010 Underlying: Common Stock · 4,590 shares Expires 2016-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2013 Filed May 8, 2013 23:28 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $31.84 | $0.00 |
DisclosureSEC source: 0001225208-13-011725 · doc4.xml · derivative · entry 11 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,501 Underlying: Common Stock · 1,500 shares Expires 2015-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2013 Filed May 8, 2013 23:28 UTC | Merck & Co., Inc. MRK · Entity 2807 | SaleCommon Stock | 36,204 | $45.20 | $1,636,529.41 |
DisclosureSEC source: 0001225208-13-011725 · doc4.xml · nonDerivative · entry 7 Deese Willie A · CIK 0001328766 · Exe V-P & Pres. MMD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,996.5265 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.2000 to $45.2150, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.